TYPICAL EVALUATION LICENSE

FOR

INVENTIONS
LICENSE AGREEMENT

BETWEEN

[LICENSEE]

AND

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

FOR

CASE NO. SD__-___
CASE NO. SD__-___
CASE NO. SD__-___
CASE NO. SD__-___

Note: This writing is provided for discussion purposes only. The express language of this writing is subject to the approval of, and may be changed by, UC management or UC counsel upon review. Therefore, this writing merely reflects items currently being discussed between The Regents and [Licensee] in preliminary negotiations. It is not intended to represent an agreement as to the subject matter contained in it.
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recitals</td>
<td>1</td>
</tr>
<tr>
<td>Article 1: Definitions</td>
<td>x</td>
</tr>
<tr>
<td>Article 2: Grant</td>
<td>x</td>
</tr>
<tr>
<td>Article 3: Consideration</td>
<td>x</td>
</tr>
<tr>
<td>Article 4: Reports, Records and Payments</td>
<td>x</td>
</tr>
<tr>
<td>Article 5: Patent Matters</td>
<td>x</td>
</tr>
<tr>
<td>Article 6: Governmental Matters</td>
<td>x</td>
</tr>
<tr>
<td>Article 7: Termination or Expiration of Agreement</td>
<td>x</td>
</tr>
<tr>
<td>Article 8: Limited Warranty and Indemnification</td>
<td>x</td>
</tr>
<tr>
<td>Article 9: Use of Names and Trademarks</td>
<td>x</td>
</tr>
<tr>
<td>Article 10: Miscellaneous Provisions</td>
<td>x</td>
</tr>
<tr>
<td>Exhibit A: xxxxxxxxx</td>
<td>x</td>
</tr>
</tbody>
</table>
LICENSE AGREEMENT

This agreement ("Agreement") is made by and between <COMPANY NAME>, a <STATE> corporation having an address at <ADDRESS> ("LICENSEE") and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").

This Agreement is effective on the date of the last signature ("Effective Date").

RECIPIALS

WHEREAS, the inventions disclosed in UCSD Disclosure Docket No. SD__-___ and titled “TITLE " ("Invention"), were made in the course of research at UCSD by Dr. ____________ and his/her associates (hereinafter and collectively, the "Inventors") and are covered by Patent Rights as defined below;

WHEREAS, the Inventors are employees of UCSD, and they are obligated to assign all of their right, title and interest in the Invention to UNIVERSITY;

WHEREAS, UNIVERSITY is desirous that the Invention be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public;

WHEREAS, LICENSEE is desirous of obtaining certain rights from UNIVERSITY for the evaluation of commercial development, use, and sale of the Invention, and the UNIVERSITY is willing to grant such rights; and

WHEREAS, LICENSEE understands that UNIVERSITY may publish or otherwise disseminate information concerning the Invention at any time and that LICENSEE is paying consideration thereunder for its early access to the Invention, not continued secrecy therein.

NOW, THEREFORE, the parties agree:

ARTICLE 1. DEFINITIONS

The terms, as defined herein, shall have the same meanings in both their singular and plural forms.

1.1 "Business Plan" means a reasonably detailed plan of development and commercialization for Licensed Products (defined below). The Business Plan must include, but is not limited to, an up-to-date research report identifying: proposed Licensed
Products, projected market sizes, sales, costs, profits, and anticipated market introduction
dates for the Licensed Products.

1.2 "Commercial License Agreement" means any commercial license agreement between
the parties that may result if LICENSEE exercises the rights granted under this
Agreement.

1.3 “Field” means [give specific field of use for the license].

1.4 “Licensed Method” means any method that is claimed in Patent Rights (as
defined below), the use of which would constitute, but for the license granted to
LICENSEE under this Agreement, an infringement, an inducement to infringe or
contributory infringement, of any pending or issued claim within Patent Rights.

1.5 “Licensed Product” means any service, composition or product that is claimed
in in Patent Rights, or that is produced by the Licensed Method, or the manufacture, use,
sale, offer for sale, or importation of which would constitute, but for the license granted
to LICENSEE under this Agreement, an infringement, an inducement to infringe or
contributory infringement, of any pending or issued claim within the Patent Rights.

1.6 “Patent Costs” means all out-of-pocket expenses for the preparation, filing,
prosecution, and maintenance of all United States and foreign patents included in Patent
Rights. Patent Costs shall also include out-of-pocket expenses for patentability opinions,
inventorship determination, preparation and prosecution of patent application, re-
examination, re-issue, interference, and opposition activities related to patents or
applications in Patent Rights.

1.7 "Patent Rights" means UNIVERSITY's rights in any of the following: the US
patent application (serial number ________, titled "__________") disclosing and
claiming the Invention, filed by Inventors and assigned to UNIVERSITY; and continuing
applications thereof including divisions, substitutions, and continuations-in-part (but only
to the extent the claims thereof are entirely supported in the specification and entitled to
the priority date of the parent application); any patents issuing on said applications
including reissues, reexaminations and extensions; and any corresponding foreign
applications or patents.

1.8 "Term" means the period of time beginning on the Effective Date and ending on
the expiration date of the longest-lived Patent Rights.

1.9 "1.12 "Term" means XXXXX.

Territory” means [where Patent Rights exist etc.].
ARTICLE 2. GRANTS

2.1 UNIVERSITY grants to the LICENSEE a limited right to make and use Licensed Products, and to practice the Licensed Method during the Term, in the Field, and within the Territory for the sole purpose of evaluating LICENSEE'S interest in negotiating a commercial license under Patent Rights.

2.2 UNIVERSITY further grants to LICENSEE a non-exclusive right to negotiate the terms of a Commercial License Agreement in the Field and within the Territory if LICENSEE exercises its right granted herein under 2.8 during the Term.

2.3 This Agreement constitutes LICENSEE'S entire interest under Patent Rights and does not constitute a commercial license to sell Licensed Products or to use Licensed Method in commerce or to receive anything of value from third parties by the transfer of Licensed Product or by using Licensed Method.

2.4 LICENSEE is prohibited from filing, without UNIVERSITY’S written consent, a patent application covering the Licensed Products or Licensed Method, the use, the production and/or the formation or packaging of the same for a period commensurate with the confidentiality provisions of Paragraph 10.2 (Secrecy).

2.5 UNIVERSITY expressly reserves all rights to enter into contractual agreements with any parties relating to the Invention, Patent Rights in uses outside of the Field and/or outside of the Territory.

2.6 UNIVERSITY expressly reserves all rights to enter in contractual agreements with other parties relating to the Invention, Patent Rights for all uses in all Fields and/or Territories.

2.7 The license granted in Paragraph 2.1 does not include the right of LICENSEE to grant Sublicenses to third parties.

2.8 If LICENSEE elects to exercise its right to negotiate a Commercial License Agreement under Patent Rights to use Invention, it shall do so by sending UNIVERSITY both a written notification and a Business Plan during the Term. Failure of LICENSEE to properly notify UNIVERSITY will be deemed by UNIVERSITY as an election by LICENSEE not to secure a license and the UNIVERSITY will then be free to market and license Patent Rights to others without further obligation to LICENSEE. Upon notification by LICENSEE to UNIVERSITY under this Paragraph 2.8, LICENSEE shall specify in writing those particular patent applications to which its wishes a commercial license and those in which it has no interest.
2.9 **Reservation of Rights.** UNIVERSITY reserves the right to:
(a) use the Invention, and Patent Rights for educational and research purposes;
(b) publish or otherwise disseminate any information about the Invention at any time; and
(c) allow other nonprofit institutions to use and publish or otherwise disseminate any information about Invention and Patent Rights for educational and research purposes.

**ARTICLE 3. CONSIDERATION**

3.1 **Fees.** The parties hereto understand that the fees payable by LICENSEE to UNIVERSITY under this Agreement are partial consideration for the license granted herein to LICENSEE under Patent Rights. LICENSEE shall pay UNIVERSITY:
(a) a license issue fee of ___ dollars (US$_______), within thirty (30) days after the Effective Date;
(b) license maintenance fees of ___ dollars (US$_______) per year and payable on the first anniversary of the Effective Date and annually thereafter on each anniversary;
(c) milestone payments in the amounts payable according to the following schedule or events:

<table>
<thead>
<tr>
<th>Amount</th>
<th>Date or Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i)</td>
<td></td>
</tr>
<tr>
<td>(ii)</td>
<td></td>
</tr>
</tbody>
</table>

All fees specified in Paragraphs 3.1(a) through 3.1(c) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1.

3.2 **Patent Costs.** LICENSEE shall reimburse UNIVERSITY all past (prior to the Effective Date) and future (on or after the Effective Date) Patent Costs within thirty (30) days following the date an itemized invoice is sent from UNIVERSITY to LICENSEE. In University’s discretion, for Patent Costs anticipated to exceed $20,000 (“Anticipated Costs”), UNIVERSITY will inform LICENSEE no less than thirty (30) days prior to the date when Anticipated Costs are incurred. UNIVERSITY may, at its discretion and in accordance with Paragraph 5.1(c), require full advance payment of Anticipated Costs at least fifteen (15) business days before required filing dates (“Advance Payment Deadline”). In the event UNIVERSITY has provided LICENSEE with a thirty (30) days’ notice of Anticipated Costs, and LICENSEE does not pay the Anticipated Costs on or
before the Advance Payment Deadline, UNIVERSITY will act at its sole discretion with regard to filing, prosecution and maintenance of those Patent Rights associated with the thirty (30) days’ notice. In the event that the Anticipated Costs paid by LICENSEE is greater than the actual cost, the excess amount is creditable against future Patent Costs. In the event that the actual costs exceed the Anticipated Costs paid in advance by LICENSEE, LICENSEE shall pay such excess costs within thirty (30) days following the date an itemized invoice is sent as set forth in Paragraph 4.3.

3.3 Due Diligence.

(a) LICENSEE shall:

(i) diligently proceed with the evaluation of development and manufacture of Licensed Products;

(ii) annually spend not less than _______ dollars (US$_______) for the development of Licensed Products during the first __ years of this Agreement. LICENSEE may, at its sole option, fund the research of any one of the Inventors and credit the amount of such funding actually paid to UCSD against its obligation under this paragraph; an

(iii) obtain all necessary governmental approvals for the manufacture and use of Licensed Products.

(b) If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.3(a)(i)-(iii), then UNIVERSITY shall have the right and option to terminate this Agreement. This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2.

3.4 Prospective Terms of a Commercial License Agreement. If LICENSEE exercises its right to negotiate a Commercial License Agreement in accordance with Paragraph 2.8, UNIVERSITY and LICENSEE shall negotiate to arrive at mutually agreeable terms and conditions for a Commercial License Agreement during the Term. The Commercial License Agreement will include, without limitation, the following provisions:

(a) a license issue fee (payable in cash, company stock or both);
(b) an earned royalty rate based upon net sales of Licensed Products;
(c) minimum annual royalties beginning in the year of first commercial sale of a Licensed Product and continuing for the life of the License Agreement;
(d) annual license maintenance fees proportionate with the value of the Licensed Products at the time of license, where LICENSEE’S obligation
to pay this fee shall end when LICENSEE is commercially selling a Licensed Product;

(e) mutually agreed upon diligence terms based on objective performance standards designed to achieve commercialization of the Licensed Products;

(f) confidentiality terms;

(g) indemnification of UNIVERSITY by LICENSEE akin to the terms herein;

(h) a warranty that is limited to UNIVERSITY’S lawful right to grant a license under Patent Rights;

(i) the continued reimbursement by LICENSEE of incurred patent costs; and

(j) provisions for overriding obligations to sponsors if any.

ARTICLE 4. REPORTS, RECORDS AND PAYMENTS

4.1

(a) LICENSEE shall provide to UNIVERSITY semi-annual progress reports covering LICENSEE’S evaluation activities of Invention. The progress reports are due semi-annually, on June 30 and December 31 of each year and for the life of this Agreement. The reports referred to in this Section 4.1(a) should be marked with the following title and case number: “License Agreement between UCSD and <LICENSEE NAME> for case <XXXX-XXX>.” Reports shall be submitted as attachment to UCSD’s email address: tto-reports@ucsd.edu.

(b) The progress reports will include, but are not limited to, the following topics so that UNIVERSITY may determine the progress and status of LICENSEE’S evaluation:

- a summary of work completed;
- the results of LICENSEE’S evaluation of Invention;
- a summary of work in progress;
- a summary of resources (dollar value and labor) expended in the reporting period;
- a current schedule of anticipated events or milestones; and
- a conclusion of LICENSEE’S evaluation of Invention leading to its decision on whether or not to exercise the evaluation license granted herein.

(c) Timely Reports.

LICENSEE acknowledges the important value that timely reporting provides in the UNIVERSITY's effective management of its rights under this Agreement. LICENSEE further acknowledges that failure to render the reports required under this Section 4.1 may harm UNIVERSITY’s ability to manage its rights under this Agreement. As such, reports not submitted by the required due date under this Section 4.1 will cause to be due by LICENSEE to UNIVERSITY a late reporting fee of five hundred dollars (US$500.00) per month until such report, compliant with the requirements of this Section 4.1, is received by UNIVERSITY. Payment of this fee is subject to Section 4.3, Section 7.1 and Paragraph 10.1 herein.
4.2 **Records & Audits.**

(a) LICENSEE shall keep accurate and correct records of all Licensed Products manufactured and used under this Agreement. Such records shall be retained by LICENSEE for at least five (5) years following a given reporting period.

4.3 **Payments.**

(a) All fees and reimbursements due UNIVERSITY shall be paid in United States dollars and all checks shall be made payable to "The Regents of the University of California", referencing UNIVERSITY's taxpayer identification number, 95-6006144, and sent to UNIVERSITY according to Paragraph 10.1 (Correspondence).

(b) Late Payments. In the event reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of ten percent (10%) per year. Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY.

**ARTICLE 5. PATENT MATTERS**

5.1 **Patent Prosecution and Maintenance.**

(a) Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to Paragraph 3.2, UNIVERSITY shall diligently prosecute and maintain the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice. For purposes of clarity, if LICENSEE is not current in reimbursing UNIVERSITY for such patent prosecution costs, UNIVERSITY shall have no obligation to incur any new Patent Costs under this Agreement or to further prosecute Patent Rights or file any new patents under Patent Rights. UNIVERSITY shall provide LICENSEE with copies of all relevant documentation relating to such prosecution and LICENSEE shall keep this documentation confidential. The counsel shall take instructions only from UNIVERSITY, and all patents and patent applications in Patent Rights shall be assigned solely to UNIVERSITY. UNIVERSITY shall in any event control all patent filings and all patent prosecution decisions and related filings (e.g. responses to office actions) shall be at UNIVERSITY’s final discretion (prosecution includes, but is not limited to, interferences, oppositions and any other inter partes matters originating in a patent office).

(b) UNIVERSITY shall consider amending any patent application in Patent Rights to include claims reasonably requested by LICENSEE to protect the products contemplated to be sold by LICENSEE under this Agreement.

(c) LICENSEE may elect to terminate its reimbursement obligations with respect to any patent application or patent in Patent Rights upon three (3) months’ written notice to UNIVERSITY. UNIVERSITY shall use reasonable efforts to curtail further Patent Costs for such application or patent when such notice of
termination is received from LICENSEE. UNIVERSITY, in its sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall have no further license with respect thereto. Non-payment of any portion of Patent Costs or Anticipated Costs with respect to any application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its reimbursement obligations with respect to such application or patent. UNIVERSITY is not obligated at any time to file, prosecute, or maintain Patent Rights in a country, where, for that country’s patent application LICENSEE is not paying Patent Costs, or to file, prosecute, or maintain Patent Rights to which LICENSEE has terminated its license hereunder.

5.2 Patent Infringement.

If LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with reasonable evidence of the infringement. LICENSEE shall not notify a third party of the infringement of Patent Rights without the consent of UNIVERSITY.

5.3 Patent Marking. LICENSEE shall mark allLicensed Products made or used under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws if such Licensed Product is transferred to a third party. LICENSEE shall be responsible for all monetary and legal liabilities arising from or caused by (i) failure to abide by applicable patent marking laws and (ii) any type of incorrect or improper patent marking.

ARTICLE 6. GOVERNMENTAL MATTERS

6.1 Governmental Approval or Registration. If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process.

6.2 Export Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations.
ARTICLE 7. TERMINATION OR EXPIRATION OF THE AGREEMENT

7.1 Termination by UNIVERSITY.

(a) If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (“Notice of Default”) to LICENSEE. If LICENSEE fails to cure the default within sixty (60) days of the Notice of Default, UNIVERSITY may terminate this Agreement and the license granted herein by a second written notice (“Notice of Termination”) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice. Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY. During the term of any such Notice of Default or period to cure, to the extent the default at issue is a failure to pay past or ongoing Patent Costs as provided for under this Agreement, UNIVERSITY shall have no obligation to incur any new Patent Costs under this Agreement and shall have no obligation to further prosecute Patent Rights or file any new patents under Patent Rights.

(b) This Agreement will terminate immediately, without the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1(a), if LICENSEE files a claim including in any way the assertion that any portion of UNIVERSITY’s Patent Rights is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of the LICENSEE, or a third party at the written urging of the LICENSEE.

(c) This Agreement shall automatically terminate without the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1(a) upon the filing of a petition for relief under the United States Bankruptcy Code by or against the LICENSEE as a debtor or alleged debtor.

7.2 Termination by LICENSEE.

(a) LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day written notice to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement.

(b) Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.

7.3 Survival on Termination or Expiration. The following Paragraphs and Articles shall survive the termination or expiration of this Agreement:
(a) Article 4 (REPORTS, RECORDS AND PAYMENTS);
(b) Paragraph 7.4 (Disposition of Licensed Products on Hand);
(c) Article 8 (LIMITED WARRANTY AND INDEMNIFICATION);
(d) Article 9 (USE OF NAMES AND TRADEMARKS);
(e) Section 10.2 hereof (Secrecy);
(f) Paragraph 10.5 (Failure to Perform); and
(g) Paragraph 10.6 (Governing Laws).

7.4 Disposition of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose of all previously made or partially made Licensed Product within a period of one hundred and twenty (120) days of the effective date of such termination provided that the sale of such Licensed Product by LICENSEE shall be prohibited.

ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION

8.1 Limited Warranty.

(a) UNIVERSITY warrants that it has the lawful right to grant this license. This warranty does not include Patent Rights to the extent assigned, or otherwise licensed, by UNIVERSITY’s inventors to third parties.

(b) The license granted herein is provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights will not infringe any other patent or other proprietary rights.

(c) UNIVERSITY WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY
HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY’S INVENTORS TO THIRD PARTIES.

(d) Nothing in this Agreement shall be construed as:

(i) a warranty or representation by UNIVERSITY as to the validity or scope of any Patent Rights;

(ii) a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties;

(iii) an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Section 5.2 hereof;

(iv) conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; or

(v) an obligation to furnish any know-how not provided in Patent Rights

8.2 Indemnification.

(a) LICENSEE will indemnify, hold harmless, and defend UNIVERSITY and its officers, employees, and agents; the sponsors of the research that led to the Invention; and the inventors of patents or patent applications under Patent Rights, and their employers; against any and all claims, suits, losses, damages, costs, fees, and expenses resulting from, or arising out of, the exercise of this license. This indemnification will include, but will not be limited to, any product liability.

(b) LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self insurance as follows:

(i) comprehensive or commercial general liability insurance (contractual liability included) with limits of at least: (A) each occurrence, XXX million dollars (US$XXXX); (B) products/completed operations aggregate, XXX million dollars (US$XXXX); (C) personal and advertising injury, XXX million dollars (US$XXXX); and (D) general aggregate (commercial form only), XXX million dollars (US$XXX). If the above insurance is written on a claims-made form, it shall continue for
three (3) years following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date.

(ii) Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; and

(iii) the coverage and limits referred to above shall not in any way limit the liability of LICENSEE.

(c) LICENSEE shall furnish UNIVERSITY with certificates of insurance showing compliance with all requirements. Such certificates shall: (i) provide for thirty (30) day advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY has been endorsed as an additionally insured party under the coverage referred to above; and (iii) include a provision that the coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried or maintained by UNIVERSITY.

(d) UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article. LICENSEE will not settle any claim against UNIVERSITY without UNIVERSITY’s written consent, where (a) such settlement would include any admission of liability or admission of wrong doing on the part of the indemnified party, (b) such settlement would impose any restriction on UNIVERSITY/indemnified party’s conduct of any of its activities, or (c) such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims that are the subject matter of the settled claim.

ARTICLE 9. USE OF NAMES AND TRADEMARKS

9.1 Except as provided in 9.3, nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by LICENSEE of the name, “The Regents of the University of California” or the name of any campus of the University Of California in advertising, publicity, or other promotional activities is prohibited, without the express written consent of UNIVERSITY.

9.2 UNIVERSITY may disclose to the Inventors the terms and conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the Inventors not disclose such terms and conditions to others.
9.3 UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so, such as under the California Public Records Act. LICENSEE hereby grants permission for UNIVERSITY (including UCSD) to include LICENSEE’s name and a link to LICENSEE’s website in UNIVERSITY’s and UCSD’s annual reports and on UNIVERSITY’s (including UCSD’s) websites that showcase technology transfer-related stories.

ARTICLE 10. MISCELLANEOUS PROVISIONS

10.1 Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have been properly given and effective:

(a) on the date of delivery if delivered in person,

(b) five (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party, or

(b) upon confirmation by recognized national overnight courier, confirmed facsimile transmission, or confirmed electronic mail, to the following addresses or facsimile numbers of the parties.

If sent to LICENSEE:
[Name and address of licensee – please include specific information for separate locations for invoices and notices, if applicable]

Attention: __________________
Phone: __________________
Fax: __________________

If sent to UNIVERSITY by mail:
University of California, San Diego
Office of Innovation and Commercialization
9500 Gilman Drive, Mail Code 0910
La Jolla, CA 92093-0910
Attention: Assistant Vice Chancellor

If sent to UNIVERSITY by overnight delivery:
University of California, San Diego
Office of Innovation and Commercialization
10300 North Torrey Pines Road
Torrey Pines Center North, Third Floor
La Jolla, CA 92037
Attention: Assistant Vice Chancellor
10.2 Secrecy.

(a) “Confidential Information” shall mean information, relating to the Invention and disclosed by UNIVERSITY to LICENSEE during the term of this Agreement, which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall within thirty (30) days of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE:

(b) LICENSEE shall:

(i) use the Confidential Information for the sole purpose of performing under the terms of this Agreement;

(ii) safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its own data of a similar nature;

(iii) not disclose Confidential Information to others (except to its employees, agents or consultants who are bound to LICENSEE by a like obligation of confidentiality) without the express written permission of UNIVERSITY, except that LICENSEE shall not be prevented from using or disclosing any of the Confidential Information that:

(A) LICENSEE can demonstrate by written records was previously known to it;

(B) is now, or becomes in the future, public knowledge other than through acts or omissions of LICENSEE;

(C) is lawfully obtained by LICENSEE from sources independent of UNIVERSITY; or

(D) is required to be disclosed by law or a court of competent jurisdiction; and

(c) The secrecy obligations of LICENSEE with respect to Confidential Information shall continue for a period ending five (5) years from the termination date of this Agreement.

10.3 Assignability. This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE only with the written consent of UNIVERSITY.
10.4 **No Waiver.** No waiver by either party of any breach or default of any covenant or agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default.

10.5 **Failure to Perform.** In the event of a failure of performance due under this Agreement and if it becomes necessary for either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorneys’ fees in addition to costs and necessary disbursements.

10.6 **Governing Laws.** THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application.

10.7 **Force Majeure.** A party to this Agreement may be excused from any performance required herein if such performance is rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s obligations herein shall resume.

10.8 **Headings.** The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

10.9 **Entire Agreement.** This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof.

10.10 **Amendments.** No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and signed on behalf of each party.

10.11 **Severability.** In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.
IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and year written.

[COMPANY NAME]:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:

By: ___ DRAFT-DO NOT SIGN  
   By:___________________________  
   (Signature)  (Signature)

Name:________________________  Jane Moores, Ph.D.

Title:________________________  Assistant Vice Chancellor-Technology Transfer

Date:________________________  Date:________________________
Exhibit A